S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00

Prothena Stock Forecast, Price & News

-6.34 (-10.39 %)
(As of 10/27/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
499,301 shs
Average Volume
427,459 shs
Market Capitalization
$2.42 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Prothena logo

About Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$4.61 per share


Net Income
$-111.14 million
Net Margins
Pretax Margin




Free Float
Market Cap
$2.42 billion
Next Earnings Date
11/3/2021 (Estimated)
Fiscal Year End


Overall MarketRank

2.28 out of 5 stars

Medical Sector

285th out of 1,372 stocks

Pharmaceutical Preparations Industry

132nd out of 669 stocks

Analyst Opinion: 2.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Prothena (NASDAQ:PRTA) Frequently Asked Questions

Is Prothena a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena
or view top-rated stocks.

What stocks does MarketBeat like better than Prothena?

Wall Street analysts have given Prothena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prothena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Prothena

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its earnings results on Thursday, August, 5th. The biotechnology company reported $0.58 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.02. The biotechnology company earned $60.07 million during the quarter, compared to the consensus estimate of $60.14 million. Prothena had a negative net margin of 115.87% and a negative trailing twelve-month return on equity of 30.73%.
View Prothena's earnings history

How has Prothena's stock price been impacted by Coronavirus?

Prothena's stock was trading at $9.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRTA shares have increased by 462.6% and is now trading at $54.68.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PRTA?

9 brokerages have issued 12-month price objectives for Prothena's shares. Their forecasts range from $14.00 to $103.00. On average, they expect Prothena's share price to reach $66.44 in the next year. This suggests a possible upside of 21.5% from the stock's current price.
View analysts' price targets for Prothena
or view top-rated stocks among Wall Street analysts.

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Gene G. Kinney, President, Chief Executive Officer & Director
  • Brandon S. Smith, Chief Operating Officer
  • Tran B. Nguyen, Chief Financial & Strategy Officer
  • Wagner M. Zago, Chief Scientific Officer
  • Hideki Garren, Chief Medical Officer

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of retail and institutional investors. Top institutional investors include Pinnacle Associates Ltd. (0.34%), Hillsdale Investment Management Inc. (0.21%), State of New Jersey Common Pension Fund D (0.10%), Robeco Institutional Asset Management B.V. (0.04%), Strs Ohio (0.03%) and Virginia Retirement Systems ET AL (0.02%). Company insiders that own Prothena stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Karin L Walker and Wagner M Zago.
View institutional ownership trends for Prothena

Which major investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Virginia Retirement Systems ET AL, and Focused Wealth Management Inc. Company insiders that have sold Prothena company stock in the last year include Carol D Karp, Christopher S Henney, Dennis J Selkoe, Karin L Walker, and Wagner M Zago.
View insider buying and selling activity for Prothena
or view top insider-selling stocks.

Which major investors are buying Prothena stock?

PRTA stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Hillsdale Investment Management Inc., Robeco Institutional Asset Management B.V., Strs Ohio, and Xcel Wealth Management LLC.
View insider buying and selling activity for Prothena
or or view top insider-buying stocks.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $54.68.

How much money does Prothena make?

Prothena has a market capitalization of $2.42 billion and generates $850,000.00 in revenue each year. The biotechnology company earns $-111.14 million in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 66 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

Where are Prothena's headquarters?

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company can be reached via phone at (531) 236-2500 or via email at [email protected].

This page was last updated on 10/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.